Life sciences company Avacta Group plc (AIM: AVCT) reported on Monday that it has completed the sale of its Belgian diagnostics subsidiary Coris Bioconcept SRL to 3B BlackBio Dx Ltd, following the satisfaction of all closing conditions.

The transaction closed on 29 August 2025. Financila details were not disclosed.

Avacta is focused on oncology drug development through its proprietary pre|CISION platform, which delivers highly potent cancer therapies directly into the tumour microenvironment by targeting fibroblast activation protein (FAP). The approach aims to maximise therapeutic impact while reducing systemic toxicity, supporting the optimisation of dosing and patient outcomes.

The company's pipeline includes pre|CISION peptide drug conjugates and Affimer-based drug conjugates, positioning Avacta to expand the reach of next-generation targeted oncology treatments.